Inovio Pharmaceuticals Faces Class Action Lawsuit Amidst Securities Fraud Allegations
1. Overview of the Situation
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is currently facing a class action lawsuit filed by the Law Offices of Howard G. Smith on behalf of investors who purchased securities between October 10, 2023, and December 26, 2025. This lawsuit comes on the heels of significant drops in the company's stock price, which have raised concerns among shareholders regarding potential securities fraud.
2. Timeline of Events
August 2024: Manufacturing Issues Disclosed
The troubles for Inovio began on August 8, 2024, when the company released its second quarter financial results. Inovio announced a delay in submitting its Biologics License Application (BLA) for its investigational treatment for recurrent respiratory papillomatosis (RPR), known as INO-3107. Initially projected for mid-2024, the submission was pushed back to mid-2025 due to a manufacturing issue with the company’s proprietary medical device, CELLECTRA. Following this news, Inovio’s share price fell by $0.27, or 3.1%, closing at $8.44 per share on August 9, 2024.
December 2025: FDA Acceptance Impacts Stock Further
The situation deteriorated further on December 29, 2025, when Inovio disclosed that the FDA had accepted the INO-3107 BLA but under a standard review timeline instead of the anticipated accelerated review. The company also stated it would not seek approval under this standard timeline and planned to request a meeting with the FDA to discuss the possibility of pursuing accelerated approval. This announcement led to a dramatic drop in Inovio’s stock price, falling $0.56, or 24.45%, to close at $1.73 per share, exacerbating investor losses.
3. Allegations in the Lawsuit
The complaint associated with the class action alleges that Inovio's management made materially false and misleading statements throughout the Class Period. Key allegations include:
- Manufacturing Deficiencies: The lawsuit claims that Inovio’s manufacturing processes for the CELLECTRA device were inadequate, which contributed to the delay in the BLA submission.
- Misleading Projections: It is alleged that the company was unlikely to meet its previously stated timelines for the BLA submission, contradicting public statements made by management.
- Overstated Regulatory Prospects: The complaint asserts that Inovio lacked sufficient rationale to justify the eligibility of INO-3107 for accelerated approval or priority review, suggesting that the positive outlook shared with investors was fundamentally flawed.
- Material Omissions: The company is accused of failing to disclose adverse facts about its business and operational capabilities, which misled investors regarding the company’s future prospects.
4. Call to Action for Investors
Investors who suffered financial losses due to the drops in Inovio's stock price are encouraged to participate in the ongoing securities fraud lawsuit. The deadline for filing a lead plaintiff motion is April 7, 2026. Affected shareholders are urged to reach out to the Law Offices of Howard G. Smith to discuss their legal rights and potential participation in the lawsuit.
5. Conclusion
As Inovio Pharmaceuticals navigates this challenging period, the unfolding class action lawsuit highlights the critical importance of transparency and reliability in corporate communications. With significant financial stakes involved, both the company and its investors face a pivotal moment as they anticipate the outcomes of this legal battle. Investors will be watching closely as the situation develops, particularly in light of the company's future regulatory interactions with the FDA regarding INO-3107.
